Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 16Lymphoma, Non-Hodgkin 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, Follicular 5Burkitt Lymphoma 5Recurrence 4Neoplasms 4Myelodysplastic Syndromes 4Lymphoma, Large-Cell, Anaplastic 4Congenital Abnormalities 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Multiple Myeloma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Immunoblastic Lymphadenopathy 3Hematologic Neoplasms 3Thrombocythemia, Essential 2Sezary Syndrome 2Primary Myelofibrosis 2

Interventions

blinatumomab 15Cyclophosphamide 15Cytarabine 14Azacitidine 11venetoclax 10fludarabine 10fludarabine phosphate 7Methotrexate 7Daunorubicin 7Rituximab 6Vincristine 5Mercaptopurine 5Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Dexamethasone 3Cladribine 3Busulfan 3Asparaginase 3thymoglobulin 2pembrolizumab 2pegaspargase 2nilotinib 2midostaurin 2daratumumab 2Vindesine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm, Residual × Drug Therapy × Other hematologic neoplasm × Clear all
NCT03367299 2025-01-22

LAL2317

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed
149 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Novartis

Phase 3 Completed
511 enrolled 26 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡